# Peter Nash

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/peter-nash/

## Facts

| Field | Value |
| --- | --- |
| Citations | 28,945 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 67 |
| i10-index | 189 |
| Last Known Institution | Griffith University |
| OpenAlex ID | https://openalex.org/A5011826741 |
| ORCID iD | https://orcid.org/0000-0002-2571-788X |
| Works | 571 |

## Researcher papers

- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-3/)
- [Psoriatic arthritis: epidemiology, clinical features, course, and outcome](https://scholariq.org/papers/psoriatic-arthritis-epidemiology-clinical-features-course-and-outcome/)
- [Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-2014-update-of-the-recommendations-of-an/)
- [Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study](https://scholariq.org/papers/tofacitinib-cp-690-550-in-patients-with-rheumatoid-arthritis-receiving/)
- [Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial](https://scholariq.org/papers/ixekizumab-for-the-treatment-of-patients-with-active-psoriatic-arthritis-and-an/)
- [2018 update of the APLAR recommendations for treatment of rheumatoid arthritis](https://scholariq.org/papers/2018-update-of-the-aplar-recommendations-for-treatment-of-rheumatoid-arthritis/)
- [Evidence-based Management of Acute Musculoskeletal Pain](https://scholariq.org/papers/evidence-based-management-of-acute-musculoskeletal-pain/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

## Researcher university

- [Griffith University](https://scholariq.org/institutions/griffith-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.